4143-09-3Relevant academic research and scientific papers
Synthesis and biological evaluation of Santacruzamate-A based analogues
Randino, Rosario,Gazzerro, Patrizia,Mazitschek, Ralph,Rodriquez, Manuela
supporting information, p. 6486 - 6491 (2017/11/20)
Several derivatives of Santacruzamate-A, a natural product that is structurally related to SAHA, were synthesized to explore the potential of carbamates and oxalylamides as novel biasing element for targeting the catalytic site of zinc-dependent histone deacetylases (HDACs). An additional class of Santacruzamate-A derivatives was synthesized to investigate the influence of the cap group and the linker element on HDAC inhibitory activity. All compounds were evaluated in dose response for their in vitro cytotoxic activity in MTT assay in HCT116 cells. HDAC inhibitory activity was evaluated in vitro by western blot analysis for histone hyperacetylation assay and biochemically for representative human HDACs isoforms. Two novel compounds were identified to exhibit potent time dependent anti proliferative activity. However, unlike hydroxamic acid analogues, the tested Santacruzamate-A derivatives showed no noticeable HDAC inhibitory activity. The ethylcarbamate moiety as unusual zinc-binding group displayed no ability to coordinate the zinc ion and thus, presumably, was not able to reproduce known inhibitor-substrate zinc-binding group interactions with the HDAC catalytic site. This study confirmed that the accommodation of the zinc-binding group is deeply critical of the positioning of the linker and the projection of the cap group toward the different surface pockets of the enzyme.
Synthesis, enzyme assays and molecular docking studies of fluorinated bioisosteres of santacruzamate a as potential HDAC tracers
Ahamed, Muneer,Vermeulen, Koen,Schnekenburger, Michael,Moltzau, Lise Román,Levy, Finn Olav,Marton, János,Froeyen, Mathy,Olberg, Dag Erlend,Diederich, Marc,Bormans, Guy
, p. 787 - 797 (2017/08/07)
Background: Histone deacetylases (HDACs) emerged as important epigenetic regulators of gene expression. Method: In order to identify potential positron emission tomography (PET) tracers for imaging HDACs, we evaluated in vitro and in cellulo activities of
Urethane hapten composition and artificial antigen composition, and preparation methods and application thereof
-
Paragraph 0045; 0046; 0047; 0048, (2017/03/08)
The invention discloses a urethane hapten composition and artificial antigen composition, and preparation methods and application thereof. The urethane artificial antigen composition has molecular structures as shown in a formula (III) and a formula (IV).
Synthesis and biological evaluation of santacruzamate A and analogs as potential anticancer agents
Liu, Qi,Lu, Wenhua,Ma, Mingzhe,Liao, Jianwei,Ganesan,Hu, Yumin,Wen, Shijun,Huang, Peng
, p. 1109 - 1112 (2015/02/05)
Santacruzamate A, a recently discovered natural product from a Panamanian marine cyanobacterium Symploca sp., features a similar structure to the clinically used histone deacetylase (HDAC) inhibitor vorinostat (SAHA). We have synthesized the natural product and a small set of analogues for SAR studies. To our surprise, the synthetic natural product santacruzamate A (1a) and the analogues did not show an obvious inhibition even at 2 μM in HDAC enzyme assays while the IC50 value was 0.12 nM in the original report. However, a novel compound, 5, containing a terminal thiourea motif was found to inhibit the growth of malignant cells at submicromolar concentrations. Moreover, 5 was not cytotoxic to normal human colonic epithelial cells CCD841, suggesting that its cytotoxicity was specific to cancer cells. Further investigation indicated that the compound induced apoptosis, affected cell cycle progression and increased ROS production. We believe its mechanism of action is unrelated to HDAC inhibition and the original activity reported for santacruzamate needs to be reevaluated.
SANTACRUZAMATE A COMPOSITIONS AND ANALOGS AND METHODS OF USE
-
Page/Page column 32, (2014/02/16)
The compositions and methods described herein relate generally to Santacruzamate A compositions and analogs, which, among other features, are useful as histone deacetylase (HDAC) inhibitors.
Santacruzamate A, a potent and selective histone deacetylase inhibitor from the panamanian marine cyanobacterium cf. symploca sp.
Pavlik, Christopher M.,Wong, Christina Y. B.,Ononye, Sophia,Lopez, Dioxelis D.,Engene, Niclas,McPhail, Kerry L.,Gerwick, William H.,Balunas, Marcy J.
, p. 2026 - 2033 (2014/01/06)
A dark brown tuft-forming cyanobacterium, morphologically resembling the genus Symploca, was collected during an expedition to the Coiba National Park, a UNESCO World Heritage Site on the Pacific coast of Panama. Phylogenetic analysis of its 16S rRNA gene sequence indicated that it is 4.5% divergent from the type strain for Symploca and thus is likely a new genus. Fractionation of the crude extract led to the isolation of a new cytotoxin, designated santacruzamate A (1), which has several structural features in common with suberoylanilide hydroxamic acid [(2), SAHA, trade name Vorinostat], a clinically approved histone deacetylase (HDAC) inhibitor used to treat refractory cutaneous T-cell lymphoma. Recognition of the structural similarly of 1 and SAHA led to the characterization of santacruzamate A as a picomolar level selective inhibitor of HDAC2, a Class I HDAC, with relatively little inhibition of HDAC4 or HDAC6, both Class II HDACs. As a result, chemical syntheses of santacruzamate A as well as a structurally intriguing hybrid molecule, which blends aspects of both agents (1 and 2), were achieved and evaluated for their HDAC activity and specificity.
